Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 10/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 8/20 | 0.44 |
| ▸ | CTSV | O60911 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452919 | 0.94 | ACE (0.47) | KMT2ATSHRACEACE2CTSV | |
| SCHEMBL5105221 | 0.89 | CTSV (0.40) | KMT2ATSHRACEACE2CTSV | |
| SCHEMBL4457998 | 0.88 | CCKBR (0.41) | KMT2ATSHRACEACE2CTSV | |
| SCHEMBL6798801 | 0.87 | ACE (0.43) | KMT2ATSHRACEACE2CTSL | |
| SCHEMBL6799404 | 0.86 | CTSL (0.62) | TSHRCTSVCTSLCTSS | |
| SCHEMBL4454262 | 0.85 | ITGB3 (0.42) | KMT2ATSHRACEACE2CTSL | |
| SCHEMBL6798893 | 0.85 | CHRNA1 (0.42) | ACE2CTSLCTSS | |
| SCHEMBL6798370 | 0.85 | GPR132 (0.42) | KMT2ATSHRACEACE2CTSL | |
| SCHEMBL4449534 | 0.84 | ACE (0.38) | KMT2ATSHRACEACE2CTSL | |
| SCHEMBL4458967 | 0.84 | CTSK (0.47) | TSHRACEACE2CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| EP-1362052-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002057270-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | KMT2A 3948/4885TSHR 3678/4885ACE 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.